Table of Contents

Highlights of This Issue 3359

SPECIAL FEATURES

CCR Translations

3361  MET as a Target in Papillary Renal Cell Carcinoma
André P. Fay, Sabina Signoretti, and Toni K. Choueiri
See related article, p. 3411

CCR Perspectives in Drug Approval

3364  U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

Statistics in Clinical Cancer Research

3371  Blocking and Randomization to Improve Molecular Biomarker Discovery
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatone, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

Molecular Pathways

3379  Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
Mark A. Dickson

3384  Molecular Pathways: Niches in Metastatic Dormancy
Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

Review

3390  Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
Wing Leung

HUMAN CANCER BIOLOGY

3401  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
Yong-Chen Lu, Xin Yao, Jessica S. Crystall, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Laurence Albige, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Campan, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
See related article, p. 3361

3422  Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
Natalie Hartmann, Nathalia A. Giese, Thomas Giése, Isabel Poschke, Rienk Ofringa, Jens Werner, and Eduard Ryschich

3434  Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-iyi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

CANCER THERAPY: PRECLINICAL

3446  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titz, Thilne Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Table of Contents

3458 Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

3472 Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

3485 Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

3496 Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Gianmaria Liccari, John A. Hartley, and Daniel Hochhauser

3507 Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

3521 Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandrina T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

IMAGING, DIAGNOSIS, PROGNOSIS

3531 In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
Yasaman Ardestirpour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gandomakhi

3540 Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18FDG-PET Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Katja Pinker, Wolfgang Bogner, Pascal Balzer, Georgios Karanikas, Heinrich Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dubsky, Zsuzsanna Bago-Horvath, Rupert Bartsh, Michael Weber, Siegfried Trattnig, and Thomas H. Helbich

3550 Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Gloma on Bevacizumab Therapy
Johannes Schwarzenbo, Johannes Czernin, Whitney B. Pope, Tristan Grogen, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen

3560 Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Borresen-Dallet, Carlos Caldas, and Anita Langerod

CANCER THERAPY: CLINICAL

3581 A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eysa Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

3589 Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne HenndHof, Berthold Streubel, Werner Rabitsch, Wolfgang R. Sperr, Matthias Mayerhofer, Thomas Sulicke, and Peter Valen
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokuiro Yano, and Yoshihiko Maehara

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.